Capsinoids suppress fat accumulation via lipid metabolism

QIN HONG, CHEN XIA, HU XIANGYING and YUAN QUAN

Department of Nutrition and Food Hygiene, School of Public Health, Central South University, Changsha, Hunan 410008, P.R. China

Received March 23, 2014; Accepted October 24, 2014

DOI: 10.3892/mmr.2014.2996

Abstract. Capsaicin, found in red peppers, has been reported to have anti-obesity, anti-hypertension, anti-diabetes and anti-inflammatory functions. In the present study, we determined the effect of non-pungent capsinoids on the metabolism of adipocytes. We demonstrated that capsinoids suppressed fat accumulation in vivo and in vitro in mice. Liver, the main tissue of lipid metabolism, was treated by capsinoids, and HMG-CoA reductase, CPT-1, FAT/CD36 and GLUT4 were found to be increased significantly, which demonstrated promotion of the lipid metabolism in liver and adipose tissues. In addition, by adding capsinoids, the induced adipocytes also demonstrated significantly increased levels of HMG-CoA reductase, CPT-1, FAT/CD36 and GLUT4. Oil red O staining also demonstrated that capsinoids decreased fat accumulation in the adipocytes. In conclusion, these results indicate that capsinoids may be worth investigating as a potential cure for obesity.

Introduction

It has been confirmed that red peppers demonstrate anti-obesity, anti-hypertension, anti-diabetes and anti-inflammatory functions (1). This activity infers that the peppers contain certain ingredients that play a crucial role in these processes. Following years of study, researchers have demonstrated that one of the most effective ingredients is capsaicin, which has a potential function in ameliorating insulin resistance (2). The receptor of capsaicin is transient receptor potential vanilloid subfamily member 1 (TRPV1) (3). By activating TRPV1, capsaicin participates in the mediation of noxious stress response (4,5). TRPV1 is a universal expression gene with abundant expression in adipocytes, β-cells, skeletal muscles and hepatocytes (6). Notably, capsaicin intake promotes energy consumption and fat metabolism, which has potential anti-obesity effects (7). This action may be a result of the effect of decreasing insulin resistance by capsaicin (8-10). In addition, capsaicin participates in type 2 diabetes. Several studies reveal that capsaicin has a modest effect in type 2 diabetes (11,12). Capsaicin has also demonstrated both beneficial and harmful effects on human health (4). In addition, capsaicin may act as a carcinogen and chemopreventive depending on different factors (13). Simultaneously, another component, non-pungent capsinoids, as an analog of capsaicin, may also activate TRPV1 (14). This molecule may exert some of the same effects as capsaicin, but without the harmful effects on human health. Thus, capsinoids demonstrate a potential medicinal value and are worthy of further study.

Adipocytokines secreted by fat tissue play an essential role in controlling the accumulation of fat in organisms, which is beneficial for health (15). Therefore, the upregulation of adipocytokine secretion to promote energy expenditure promises a potential way of preventing body fat accumulation (16). It has been reported that capsaicin stimulates energy expenditure via activation of adipocytokine secretion (2). In animals, capsaicin activates adipocytokine secretion, which induces catecholamine and uncoupling protein expression in brown adipose tissue (2). Thus, capsaicin induces energy expenditure by promoting oxygen consumption and core temperature. AMP-activated protein kinase (AMPK) is a key factor in this process, and is activated by lack of cellular energy. Once AMPK is activated, the glucose uptake and fatty acid oxidation in organisms are increased to produce more adenosine triphosphate (17). Although the capsaicin-inducing metabolism of adipocyte has been reported, the effects of non-pungent capsinoids on the metabolism of adipocytes have not been unveiled yet. This could provide potential anti-obesity, anti-hypertension and anti-diabetes activity and offer a new therapeutic strategy.

The aim of the present study was to elucidate the changes in cellular levels following capsinoid treatment in adiposity in vivo and in vitro, as well as the changes in HMG-CoA reductase, CPT-1, FAT/CD36 and GLUT4 expression that occur during the process.

Materials and methods

Mouse models of obesity. The high-fat diet (HFD) D12451 and low-fat diet (LFD) D12450 by Research Diets, Inc. (New Brunswick, NJ, USA) were formulated according to previous studies (18). Diets of HFD+5% capsinoids and LFD+5% capsinoids were also prepared. Five-week-old mice were fed...
Capsinoids induce lipid metabolism in liver. Subsequently, the changes in the key genes which participate in lipid metabolism, including HMG-CoA reductase, CPT-1, FAT/CD36 and GLUT4, were assayed in the liver of obese mouse models. The results revealed that, for all the studied genes, the HFD group had the lowest mRNA expression (Fig. 2A-D) as well as protein expression (Fig. 2E). The HFD+5% capsinoids group demonstrated an increase in HMG-CoA reductase, CPT-1, FAT/CD36 and GLUT4, were assayed in the liver of obese mouse models. The results demonstrated that after feeding with the HFD, the body weight increased significantly compared with the other groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A). Mice in the LFD+5% capsinoids group had the lowest body weight among all the tested groups (Fig. 1A).
FAT/CD36 and GLUT4 expression levels, which suggested that 5% capsinoid diets may promote lipid metabolism in liver.

Capsinoids induce lipid metabolism in adipose tissue. We also analyzed the lipid metabolism in adipose tissue. The results revealed that all the tested genes had the lowest
mRNA expression as well as protein expression in the HFD group (Fig. 3A), which indicated that the 5% capsinoid diets increased lipid metabolism. The in vitro study also supported this finding. In induced adipocytes, by adding capsinoids, the expression of HMG-CoA reductase, CPT-1, FAT/CD36 and GLUT4 increased significantly compared with the control group (Fig. 3B). In addition, oil red O staining also indicated that 10^{-10} M capsinoids decreased fat accumulation significantly in the adipocytes (Fig. 3C).

**Discussion**

In the present study, we demonstrated that capsinoids have an inhibitory effect on fat accumulation which is due to the increasing effect of capsinoids on the lipid metabolism in liver and adipose tissues. Capsinoids, as an analog of capsaicin, also exhibited similar effects to capsaicin (20). However, capsinoids have a great advantage over capsaicin as they are non-pungent (21). It has been reported that capsinoids induce immune responses, having anti-inflammatory and antiproliferative effects on T cells (22). In addition, capsinoids are able to stimulate an antioxidant effect. It has also been reported by Haramizu et al (23) that after 2 weeks of treatment with capsinoids, human body fat accumulation was suppressed. In the present study, we also indicated that following intake of capsinoids, the body weight and fat mass index were suppressed even when feeding with a HFD. Thus, the mechanism of the suppression effect was also illustrated in the present study.

We then elucidated the expression changes of the lipid metabolism in liver and adipose tissues following treatment with capsinoids for various genes including HMG-CoA reductase, CPT-1, FAT/CD36 and GLUT4. All of these genes were significantly increased in liver and adipose tissues. These results suggested that the lipid metabolism was also upregulated by capsinoid treatment. HMG-CoA reductase is a rate-controlling enzyme which participates in the mevalonate pathway and is responsible for producing cholesterol and other isoprenoids. In normal cells of animals, HMG-CoA reductase is suppressed and degraded by low-density lipoprotein (24). In addition, HMG-CoA reductase has been considered to play a role in cholesterol synthesis and demonstrated activity in lipid metabolism (25). CPT1 is an essential enzyme in the beta-oxidation of long-chain fatty acids which participates in fatty acid activation and oxidization within the mitochondrial matrix (26). FAT/CD36 has functions in long-chain fatty acid uptake and could be irreversibly inhibited by sulfo-N-succinimidyl oleate, which is associated with myocardial fatty acid uptake (27). GLUT4 is an insulin-regulated glucose transporter which was identified in adipose tissues and striated muscle and has demonstrated a facilitated diffusion of circulating glucose in fat cells (28). Thus, these genes are significant components in lipid metabolism. In liver, the upregulated genes provide...
an indication that, following intake of capsinoids, the lipid metabolism pathway is significantly stimulated. The same effect was also observed in adipose tissues. In mice, it has been reported that capsinoids upregulate uncoupling protein in skeletal muscle and brown adipose tissue, which indicates that capsinoids play a notable role in energy expenditure, body weight and thermoregulation (29). A previous study has revealed that capsinoids suppressed body fat accumulation and raised oxygen consumption in the same way as exercise (29). Our findings correspond with these studies. However, the present study provides new evidence of the role of capsinoids in lipid metabolism.

It has been reported that capsaicin stimulated UCP1 expression in brown adipose tissue as well as in the concentration of serum adrenaline, which induced a depression of perirenal adipose tissue (30). Capsinoids are non-pungent, but have a similar function to capsaicin in stimulating UCP1 expression, resulting in changes in energy metabolism, adrenaline release and body fat accumulation. Thus, studies of capsinoids may provide information to support their potential application in decreasing fat. Capsaicin also demonstrated physiological effects on adrenaline release and increase in body temperature. These results also confirm that the metabolic effects of capsinoids are the same as those of capsaicin. Obesity occurs due to the imbalance between energy intake and consumption, which leads to weight gain and abdominal adipose tissue accumulation. Faraut et al demonstrated that capsinoid-induced UCP3 and UCP3 expression is a causative factor of weight loss (31). We have demonstrated in the present study that capsinoid intake reduced abdominal fat mass. Thus, it was also confirmed that capsinoids stimulate the lipid metabolism.

In conclusion, the results of the present study indicated that capsinoid intake stimulates fat metabolism, which may lead to a reduction in fat accumulation. The present findings suggest that compound capsinoids may be worth investigating as a cure for obesity.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (grant no. 81302421/H2603) and the National Science Foundation of Hunan Province, China (grant no. 12J6098).

References

1. Alkinar EK, Bicer Y and Yildiz C: Thin layer drying of red pepper. J Food Eng 59: 99-104, 2003.
2. Kang JH, Goto T, Han IS, Kawada T, Kim YM and Yu R: Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet. Obesity (Spring) 18: 780-787, 2010.
3. Szallasi A, Cortright DN, Blum CA and Eid SR: The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 6: 357-372, 2007.
4. Dinis P, Charrua A, Avelino A, et al: The distribution of sensory fibers immuno-reactive for the TRPV1 (capsaicin) receptor in the human prostate. Eur Urol 48: 162-167, 2005.
5. Chan CL, Facer P, Davis J, et al: Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 361: 385-391, 2003.
6. Matias I, Gontier MP, Petrosino S, et al: Role and regulation of acylethanolamines in energy balance: focus on adipocytes and β-cells. Br J Pharmacol 152: 676-690, 2007.
7. Diepvens K, Westerterp KR and Westerterp-Plantenga MS: Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea. Am J Physiol Regul Integr Comp Physiol 292: R77-R85, 2007.
8. Uno K, Katagiri H, Yamada T, et al: Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science 312: 1656-1659, 2006.
9. Kang JH, Kim CH, Han IS, Kawada T and Yu R: Capsaicin, a spicy component of hot peppers, modulates adipokine gene expression and protein release from obese-mouse adipose tissues and isolated adipocytes, and suppresses the inflammatory responses of adipose tissue macrophages. FEBS Lett 581: 4389-4396, 2007.
10. Kang JH, Tsuyoshi G, Le Ngoc H, et al: Dietary capsinoids activates metabolic dysregulation in genetically obese diabetic mice. J Med Food 14: 310-315, 2011.
11. Faraut M, I, Petrosino S, et al: Role and regulation of acylethanolamines in energy balance: focus on adipocytes and β-cells. Br J Pharmacol 152: 676-690, 2007.
12. Tanaka Y, Sakanaka M, Li C, et al: Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 296: E1003-E1012, 2009.
13. Chowla A, Schwarz EJ, Dimaculangan DD and Lazar MA: Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135: 798-800, 1994.
14. Yamauchi T, Kamon J, Minokoshi Y, et al: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-1295, 2002.
15. Obayashi K, Clegg DJ, Printz KL, et al: Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 296: E1003-E1012, 2009.
16. Kang JH, Hwang MK, Chung JS, et al: Role and regulation of acylethanolamines in energy balance: focus on adipocytes and β-cells. Br J Pharmacol 152: 676-690, 2007.
17. Iida T, Moriyama T, Kobata K, et al: TRPV1 activation and induction of nociceptive response by a non-pungent capsaicin-like compound, capsiate. Neuropharmacology 44: 960-967, 2003.
18. Tyl H and Moschen AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6: 772-783, 2006.
19. Matsuzawa Y, Funahashi T and Nakamura T: Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 892: 146-154, 1999.
20. Wanders R, Ferdinandusse S, Jansen G, et al: Regulation of HMG CoA reductase, a control mechanism coordinating cholesterol biosynthesis by the liver modulates energy expenditure and systemic insulin sensitivity. Science 312: 1656-1659, 2006.
21. Kang JH, Tsuyoshi G, Le Ngoc H, et al: Dietary capsinoids activates metabolic dysregulation in genetically obese diabetic mice. J Med Food 14: 310-315, 2011.
22. Faraut M, I, Petrosino S, et al: Role and regulation of acylethanolamines in energy balance: focus on adipocytes and β-cells. Br J Pharmacol 152: 676-690, 2007.
23. Tanaka Y, Sakanaka M, Li C, et al: Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 296: E1003-E1012, 2009.
24. Chowla A, Schwarz EJ, Dimaculangan DD and Lazar MA: Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135: 798-800, 1994.
25. Yamauchi T, Kamon J, Minokoshi Y, et al: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-1295, 2002.
26. Obayashi K, Clegg DJ, Printz KL, et al: Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 296: E1003-E1012, 2009.
27. Kang JH, Hwang MK, Chung JS, et al: Role and regulation of acylethanolamines in energy balance: focus on adipocytes and β-cells. Br J Pharmacol 152: 676-690, 2007.
28. Kang JH, Tsuyoshi G, Le Ngoc H, et al: Dietary capsinoids activates metabolic dysregulation in genetically obese diabetic mice. J Med Food 14: 310-315, 2011.
29. Faraut M, I, Petrosino S, et al: Role and regulation of acylethanolamines in energy balance: focus on adipocytes and β-cells. Br J Pharmacol 152: 676-690, 2007.
28. Shepherd PR, Gnudi L, Tozzo E, Yang H, Leach F and Kahn BB: Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. J Biol Chem 268: 22243‑22246, 1993.

29. Masuda Y, Haramizu S, Oki K, et al: Upregulation of uncoupling proteins by oral administration of capsiate, a nonpungent capsaicin analog. J Appl Physiol 95: 2408‑2415, 2003.

30. Cannon B and Nedergaard J: Brown adipose tissue: function and physiological significance. Physiol Rev 84: 277‑359, 2004.

31. Faraut B, Giannesini B, Matarazzo V, et al: Downregulation of uncoupling protein‑3 in vivo is linked to changes in muscle mitochondrial energy metabolism as a result of capsiate administration. Am J Physiol Endocrinol Metab 292: E1474‑E1482, 2007.